<DOC>
	<DOCNO>NCT02717988</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , single ascend dose study design demonstrate safety , tolerability pharmacokinetics SKI-O-703 healthy volunteer . The result study guide selection dose level future multiple dose study healthy volunteer adult patient moderately severely active rheumatoid arthritis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Single Oral Dose SKI-O-703 Healthy Volunteers</brief_title>
	<detailed_description>This double-blind , placebo-controlled study healthy adult volunteer conduct evaluate safety , tolerability , pharmacokinetics ascend single dos SKI-O-703 . A total 48 subject plan participate 6 cohort ( 8 subject ) . In cohort , 6 subject randomly assign receive SKI-O-703 2 subject randomly assign match placebo . Dosing initiate 50 mg dose cohort sequentially escalate 100 mg , 200 mg , 400 mg , 600 mg , 800 mg cohort .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Willing able provide write informed consent participation prior complete study procedure Considered investigator good health determine absence clinically significant disease clinically significant abnormal value determine detailed medical history review , complete physical examination , clinical laboratory assessment . Clinical significance outofrange laboratory test result determine principal investigator Male subject female subject nonchildbearing potential age 18 55 year , inclusive Female subject nonchildbearing potential surgically sterile least 6 month postmenopausal least 2 year folliclestimulating hormone serum level consistent postmenopausal status . Male subject must agree use condom spermicide abstain sexual intercourse 90 day dose Male subject must agree donate sperm 90 day dose Female subject must negative serum pregnancy test result Screening Day 1 Subject must body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive , weight â‰¥50 kg Subject must able understand study risk participation able communicate investigator History clinically significant disease disorder may put subject risk he/she participate study , might affect subject 's ability participate study , influence study result History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion ( ADME ) drug Any surgical medical condition possibly affect drug ADME ( eg , bariatric procedure ) Any medical/surgical procedure trauma within 4 week Day 1 determine investigator Any clinically significant infection within 3 month Day 1 determine investigator Any follow abnormal laboratory value upon repeat test Screening checkin : Hemoglobin &lt; low limit normal ( LLN ) Platelet count &lt; LLN Absolute neutrophil count &lt; LLN &gt; upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; ULN Creatinine blood urea nitrogen &gt; ULN Other clinically significant abnormal laboratory result opinion investigator Use concomitant medication Day 1 completion EndofStudy visit , include prescription medication , nutritional supplement , herbal remedy , overthecounter medication ( Note : Use vitamin supplement stop least 7 day prior Screening completion EndofStudy visit ) Receipt investigational medication within Day 1 , whichever long Use tobacco nicotinecontaining product within Day 1 EndofStudy visit Use cytochrome P450 3A isozyme ( CYP3A ) inducer inhibitor ( include St. John 's wort ) within 30 day dose Food beverage contain alcohol , grapefruit grapefruit juice , apple orange juice , vegetables mustard green family ( eg , kale , broccoli , watercress , collard green , kohlrabi , brussels sprout , mustard ) , charbroiled meat within 1 week prior dose History substance abuse , drug addiction , alcoholism Positive urine drug urine alcohol test result screen Day 1 unable abstain alcohol 72 hour prior study entry EndofStudy visit Unable abstain caffeine xanthinecontaining product 72 hour prior dose discharge study site Female subject pregnant lactate positive serum pregnancy test result Screening Positive test result Screening human immunodeficiency virus , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody , hepatitis B core antibody negative HBsAg Recent ( past 5 year ) history malignancy except successfully treat basal cell carcinoma High blood pressure , define &gt; 140 millimeter mercury ( mm Hg ) systolic blood pressure &gt; 90 mm Hg diastolic blood pressure upon repeat confirmation Cardiac arrhythmia clinically significant ECG finding upon repeat confirmation investigator Corrected QT interval ( QTc ) &gt; 450 millisecond deem clinically significant investigator Family history long QT syndrome Blood loss blood donation &gt; 450 mL within 4 week study drug dose History sensitivity drug chemical similarity study drug , component , excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>moderately severely active</keyword>
</DOC>